AnaptysBio Profit Margin

The latest profit margin for ANAB is -11.53% as of March 2026. That compares with -125.7% in the prior-year period — up 90.8% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside AnaptysBio's historical trend and sector peers before judging valuation or financial health.

Over the past year, ANAB's profit margin moved from -125.7% to -11.53% — a 90.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AnaptysBio's valuation or profitability profile.

Against Healthcare companies, ANAB currently prints -11.53% for profit margin, while the sector average sits near 13.89%. That is roughly 183.0% below the sector mean. Large gaps often invite a closer look at AnaptysBio's growth, margins, and balance sheet.

Profit Margin shows how effectively AnaptysBio converts resources into returns. At -11.53%, ANAB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -125.7% in the prior-year period — up 90.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ANAB's profit margin (-11.53%), review year-over-year change from -125.7%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.